These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16680845)

  • 1. Prostate cancer in younger and older men.
    Harv Mens Health Watch; 2006 May; 10(10):6-8. PubMed ID: 16680845
    [No Abstract]   [Full Text] [Related]  

  • 2. [PSA doubling times of prostate carcinoma managed with watchful observation alone].
    Dunst J
    Strahlenther Onkol; 2001 Dec; 177(12):684-5. PubMed ID: 11789411
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
    Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
    J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
    J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Young men with prostate cancer: are they different and how should they be managed?
    Khan MA
    BJU Int; 2007 May; 99(5):1169. PubMed ID: 17437448
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
    Loeb S; Roehl KA; Catalona WJ; Nadler RB
    J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
    Mouraviev V; Broadwater G; Sun L; Mayes JM; Moul JW; Polascik TJ
    Urology; 2008 Jun; 71(6):1020-3. PubMed ID: 18267331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
    Loeb S; Roehl KA; Yu X; Han M; Catalona WJ
    Urology; 2007 Jan; 69(1):108-12. PubMed ID: 17270629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in prostate-specific antigen testing from 1995 through 2004.
    Farwell WR; Linder JA; Jha AK
    Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
    Ercole B; Marietti SR; Fine J; Albertsen PC
    J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 17. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New PSA guidelines for older men.
    Johns Hopkins Med Lett Health After 50; 1998 Sep; 10(7):1-2. PubMed ID: 9715121
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 20. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
    Macefield RC; Lane JA; Metcalfe C; Down L; Neal DE; Hamdy FC; Donovan JL
    Eur J Cancer; 2009 Sep; 45(14):2569-73. PubMed ID: 19375907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.